Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis.
hematopoiesis
in vitro culture
myelofibrosis
progenitor cells
prognosis
skewing
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Aug 2020
14 Aug 2020
Historique:
received:
19
06
2020
revised:
06
08
2020
accepted:
13
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Normal hematopoietic function is maintained by a well-controlled balance of myelomonocytic, megaerythroid and lymphoid progenitor cell populations which may be skewed during pathologic conditions. Using semisolid in vitro cultures supporting the growth of myelomonocytic (CFU-GM) and erythroid (BFU-E) colonies, we investigated skewed differentiation towards the myelomonocytic over erythroid commitment in 81 patients with myelofibrosis (MF). MF patients had significantly increased numbers of circulating CFU-GM and BFU-E. Myelomonocytic skewing as indicated by a CFU-GM/BFU-E ratio ≥ 1 was found in 26/81 (32%) MF patients as compared to 1/98 (1%) in normal individuals. Patients with myelomonocytic skewing as compared to patients without skewing had higher white blood cell and blast cell counts, more frequent leukoerythroblastic features, but lower hemoglobin levels and platelet counts. The presence of myelomonocytic skewing was associated with a higher frequency of additional mutations, particularly in genes of the epigenetic and/or splicing machinery, and a significantly shorter survival (46 vs. 138 mo,
Identifiants
pubmed: 32824053
pii: cancers12082291
doi: 10.3390/cancers12082291
pmc: PMC7464756
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Gesellschaft zur Erforschung der Biologie und Therapie von Tumorkrankheiten
ID : ABCMML-112015
Références
Blood. 2005 Aug 15;106(4):1479-87
pubmed: 15827136
Br J Haematol. 1983 Jul;54(3):373-81
pubmed: 6574788
Blood. 2011 Oct 27;118(17):4509-18
pubmed: 21803851
Blood. 2011 Sep 1;118(9):2551-5
pubmed: 21734233
Leukemia. 2008 Feb;22(2):437-8
pubmed: 17728787
Leuk Res. 2007 Nov;31(11):1503-9
pubmed: 17397921
Blood Cancer J. 2016 Feb 05;6:e393
pubmed: 26849014
Blood. 1996 Apr 1;87(7):2732-9
pubmed: 8639889
Stem Cells. 2018 Nov;36(11):1663-1675
pubmed: 30004607
Am J Hematol. 1978;4(2):121-31
pubmed: 677118
Leukemia. 2013 Sep;27(9):1861-9
pubmed: 23619563
Haematologica. 2003 Nov;88(11):1204-12
pubmed: 14607748
Blut. 1988 Jul;57(1):45-9
pubmed: 3390617
Blood. 1973 Jan;41(1):67-71
pubmed: 4682081
Blood. 2012 Apr 5;119(14):3219-25
pubmed: 22318201
Blood. 2012 Sep 13;120(11):2203-13
pubmed: 22855602
Blood. 2014 Jan 23;123(4):541-53
pubmed: 24255920
Wien Klin Wochenschr. 2003 Aug 14;115(13-14):537-46
pubmed: 13677271
Blood. 2019 Jul 11;134(2):199-210
pubmed: 31064751
Leuk Res. 1988;12(5):373-7
pubmed: 3164085
Leukemia. 2018 Jul;32(7):1631-1642
pubmed: 29654267
Blood. 2010 Mar 4;115(9):1703-8
pubmed: 20008785
Blood. 1983 Sep;62(3):578-84
pubmed: 6603877
PLoS One. 2015 Jun 23;10(6):e0130441
pubmed: 26102347
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Cell Death Dis. 2015 Apr 16;6:e1723
pubmed: 25880090
Br J Haematol. 2018 Dec;183(5):835-838
pubmed: 29265333
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Am J Hematol. 2018 Dec;93(12):1551-1560
pubmed: 30039550
Blood. 2013 Mar 21;121(12):2186-98
pubmed: 23319568
Nat Genet. 2012 Nov;44(11):1179-81
pubmed: 23001125